Published in Front Biosci on January 01, 2008
Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol (2010) 4.21
Computer-aided antibody design. Protein Eng Des Sel (2012) 1.44
Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? Methods Mol Biol (2009) 1.32
Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis (2009) 1.21
Modern Technologies for Creating Synthetic Antibodies for Clinical application. Acta Naturae (2009) 1.12
Optimization algorithms for functional deimmunization of therapeutic proteins. BMC Bioinformatics (2010) 1.08
Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis. J Pharmacol Exp Ther (2009) 1.05
Blind prediction performance of RosettaAntibody 3.0: grafting, relaxation, kinematic loop modeling, and full CDR optimization. Proteins (2014) 1.05
Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep (2015) 1.03
Coupling mammalian cell surface display with somatic hypermutation for the discovery and maturation of human antibodies. Proc Natl Acad Sci U S A (2011) 0.98
Natural and man-made V-gene repertoires for antibody discovery. Front Immunol (2012) 0.98
Antibody modeling using the prediction of immunoglobulin structure (PIGS) web server [corrected]. Nat Protoc (2014) 0.96
Design and analysis of immune-evading enzymes for ADEPT therapy. Protein Eng Des Sel (2012) 0.95
Targeting the embryonic gene Cripto-1 in cancer and beyond. Expert Opin Ther Pat (2010) 0.89
Frontier of therapeutic antibody discovery: The challenges and how to face them. World J Biol Chem (2012) 0.88
Monoclonal antibody humanness score and its applications. BMC Biotechnol (2013) 0.86
Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody. Proc Natl Acad Sci U S A (2013) 0.85
Hendra and nipah infection: pathology, models and potential therapies. Infect Disord Drug Targets (2011) 0.84
Contributions of the complementarity determining regions to the thermal stability of a single-domain antibody. PLoS One (2013) 0.84
High affinity humanized antibodies without making hybridomas; immunization paired with mammalian cell display and in vitro somatic hypermutation. PLoS One (2012) 0.83
The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy. Br J Cancer (2009) 0.83
Properties and therapeutic efficacy of broadly reactive chimeric and humanized H5-specific monoclonal antibodies against H5N1 influenza viruses. Antimicrob Agents Chemother (2011) 0.82
Specific binding of the pathogenic prion isoform: development and characterization of a humanized single-chain variable antibody fragment. PLoS One (2011) 0.82
Antibody humanization by structure-based computational protein design. MAbs (2015) 0.80
Engineering venom's toxin-neutralizing antibody fragments and its therapeutic potential. Toxins (Basel) (2014) 0.80
Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies. Proc Natl Acad Sci U S A (2015) 0.80
Role of antibodies in developing drugs that target G-protein-coupled receptor dimers. Mt Sinai J Med (2010) 0.79
Tabhu: tools for antibody humanization. Bioinformatics (2014) 0.79
Development of scoring functions for antibody sequence assessment and optimization. PLoS One (2013) 0.78
Antibody discovery ex vivo accelerated by the LacO/LacI regulatory network. PLoS One (2012) 0.78
A novel antibody humanization method based on epitopes scanning and molecular dynamics simulation. PLoS One (2013) 0.78
Solubilization and humanization of paraoxonase-1. J Lipids (2012) 0.78
Transpo-mAb display: Transposition-mediated B cell display and functional screening of full-length IgG antibody libraries. MAbs (2016) 0.77
4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland. MAbs (2009) 0.77
Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism. Curr Top Med Chem (2014) 0.77
Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs (2015) 0.76
Introduction of germline residues improves the stability of anti-HIV mAb 2G12-IgM. Biochim Biophys Acta (2015) 0.76
Structure based antibody-like peptidomimetics. Pharmaceuticals (Basel) (2012) 0.76
Affinity Maturation of Monoclonal Antibody 1E11 by Targeted Randomization in CDR3 Regions Optimizes Therapeutic Antibody Targeting of HER2-Positive Gastric Cancer. PLoS One (2015) 0.75
New engineered antibodies against prions. Bioengineered (2013) 0.75
Characterization of a high-affinity human antibody with a disulfide bridge in the third complementarity-determining region of the heavy chain. J Mol Recognit (2012) 0.94
Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference. Blood (2007) 0.90
Distribution, cellular localization, and therapeutic potential of the tumor-associated antigen Ku70/80 in glioblastoma multiforme. J Neurooncol (2009) 0.79
Color and shape measurement with a three-color photometric stereo system. Appl Opt (2004) 0.75